The paternalistic worldview of the "doctor knows best" is (largely) on the way out. But what if it's replaced by data? Could data one day silence the intangible reasons patients have for requesting different therapies; or be used to deny certain therapies based on a set of probabilities?
On day two of MedCity CONVERGE, John Quackenbush of the Dana-Farber Cancer Institute highlighted the benefits and the challenges that accompany big data.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Recently, MedCity News spoke with a pair of top executives at global supercomputing ...
What would happen if we attacked cancer from an agnostic, 10,000-foot point of view? As president of the Biden Cancer Initiative, Greg Simon is determined to find out.
“Single mutations or single genomic alterations are only really getting us part of the way to a solution,” said John Quackenbush, director of the Center for Cancer Computational Biology and a keynote speaker at MedCity CONVERGE, on the state of precision medicine.
The report draws some interesting conclusions on the impact virtual visits, wearables, and predictive analytics will have on how healthcare is delivered in the future.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
At the DIA 2017 annual meeting, Global Chief Executive Barbara Lopez Kunz shared her passion for DIA and her thoughts on what the future of healthcare holds.
Big data analytics might just be the proactive piece of the puzzle we’ve been missing – and the potential for this realistic type of fortune telling could not come at a more exciting time.
As part of the relaunch, New York-based Prognos is making an aggressive push into the payer market to augment its predictive analytics work with life sciences and diagnostics clients.
IBM Watson Health and Illumina have formed their very own dream team for tumor sequencing, curation and interpretation. Combined, the two platforms help make cancer genomics more accessible and scalable, but it's the potential for greater scientific standardization that the field needs most.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The world of data-driven diabetes care has been blown open in the last couple of years with advances in continuous glucose monitoring, digital health and, for Type 1 diabetics, the arrival of the "artificial pancreas."
Lumiata's Risk Matrix is designed to offer predictions for 20 chronic condition patient populations, such as diabetes, chronic kidney disease and congestive heart failure.
CMS is supporting the incorporation of FDA's unique device identifiers in insurance claims forms, a boon to medical researchers who would receive a bounty of data about medical device safety and effectiveness.
Biden's aim to outwit cancer can demolish another scourge in healthcare: silos.
Among the highlights of Wednesday's Cancer Moonshot Summit was news that IBM Watson Health will team with the U.S. Department of Veterans Affairs to bring precision medicine to 10,000 veterans with cancer over the next two years.